Rama Venugopal’s Post

#Healthcare #Regulations #LegitimateGrowth 𝐔𝐧𝐧𝐞𝐜𝐞𝐬𝐬𝐚𝐫𝐲 𝐭𝐞𝐬𝐭𝐬 𝐮𝐩 𝐛𝐲 𝟑𝟎% 𝐚𝐟𝐭𝐞𝐫 𝐩𝐚𝐧𝐝𝐞𝐦𝐢𝐜 Reading this post on Clinical Labs / Medical Labs / Diagnostics and their intersting Business Models. Some highlights : "Given the lack of government laboratories, people often fall prey to such packages, risking not only their money but also their health, as many start suffering from clinical depression and anxiety. To stop this, all three bodies - directorate of medical education and research (Maharashtra) DMER, state public health services, and drug administration of FDA - need to come together to regulate diagnostic chains that mislead people into unnecessary tests and loot them in the name of health,"  “There is an urgent need for a watchdog to regulate the chain of corporate laboratories and put an end to tie-ups between doctors and facilities.” My Musings : Medical Associations should involve SEBI also into this collaborative exercise where Regulators under Financial Regulations and Operational Licenses sit across the table and pick up the gaps. Was reading a CRISIL report that has captured the growth of all listed diagnostics operatots and some reasons for their growth. Pertinent point raised by CRISIL report which says growth is due to the collection centers operated by Diagnostics players and majority of the collection centres are their franchisees . Now look at the collection centre definition given in Healthcare Regulations (CEA) which says collection centre can be operated only by a licensed lab directly and not through 3rd party collection centres. If this is the criteria laid down under operational license under healthcare regulations, how come Financial Regulator is not asking such critical disclosures from listed companies (as some of them are large mkt cap cos with more than Rs 1000 crores market cap) and they have to disclose such key disclosures related to Social Responsibility and Governance norms under ESG Disclosures . How legitimate is the growth of these listed businesses when they are staying outside the legitimate pathways defined in the country, under regulations ?

💡🧑⚕️ Did you know that almost half of the British population want pharmacists to be able to offer more services to support their health?  ➡️The Government’s Pharmacy First scheme, which launched in January 2024, granted pharmacists more responsibility to support doctors by enabling patients to be referred into community pharmacy for things such as a minor illness or an urgent repeat medicine supply.   ➡️ The immediate take up of Pharmacy First was impressive - over 125,000 consultations were carried out in in the scheme’s first month and 98% of pharmacies signed up to the service.  With such a strong response, do you think pharmacy should have more power to support doctors? 🤔   The #STADAHealthReport, now in its 10th year, surveys more than 46,000 respondents from 32 countries, 2,000 of whom are in the UK. https://lnkd.in/eAuuvFzb #OneSTADA #CaringForPeoplesHealth #pharmacy #pharmauk #pharmacyfirst #HealthReport2024 STADA Group

Patients' health can be improved by a multidisciplinary partnership in the medical community. Collaboration is is key: https://lnkd.in/du-ujfju #collaboration #healthcare #realworlddata

Dr Lalpath Labs Vinay Gujral VED PRAKASH GOEL Arvind Lal I am writing this post to bring to your attention a serious issue I encountered with Dr. Lalpathlabs (Green Park) which raises concerns about medical negligence and patient safety. Recently, I underwent a Pulmonary Function Test (PFT) at Dr. Lalpathlabs. The results indicated that my lung function was at a dangerously low 60%. Alarmed by these findings, I sought a second opinion at Max Hospital. The retest results showed that my lung function was actually at 80%. This significant discrepancy in test results is not just a clerical error but a case of medical negligence. Had I relied solely on the incorrect report from Dr. Lalpathlabs, it could have led to a life-threatening emergency and unnecessary panic. To make matters worse, when I contacted Dr. Lalpathlabs to address this issue, they outright denied any responsibility. I was told to take any action I deemed necessary. Only after further insistence did their customer service offer a refund and a coupon of INR 500 as compensation for this grave error. This response is not only inadequate but also dismissive of the potential risk their negligence posed to my health (both reports have been shared with Dr. Lalpathlabs for comparison) I am sharing my experience to caution others about the potential dangers of inaccurate medical reporting and the importance of seeking second opinions. Patient safety should always be a priority, and healthcare providers must be held accountable for their actions Indian Medical Association Association of Healthcare Providers - AHPI (India) Dr.Girdhar Gyani

While the importance of addressing health equity is now more widely acknowledged, significant gaps in outcomes remain, including: disparities in life expectancy within and across countries; lack of diversity in clinical trials; and over two million people globally with no access to essential medicines. Achieving health equity requires life science and healthcare organisations to deliberately design and build systems that advance equity as a priority. Our latest blog presents the key takeaways from a roundtable Deloitte held with Medical Affairs experts discussing how their role in advancing health equity could evolve. #medaffairs #healthequity

Our portfolio company Seegnal e- Health, an Israeli digital Health provider, announces today that its distributor in the UK, Digitals UK, has been awarded a framework contract by the UK Government's Department of Health  to sell Seegnal's clinical decision-support software  platform (The digital virtual pharmacist)  in the UK health  public sector. As part of the tender won,. Seegnal through it's UK distrbutor, will be listed as part of a distinguished Clinical Decision Support systems list in Government buying platforms as of November 9, 2024. Digitals UK will be able to market, answer to bids, and deploy Seegnal as of November 9th in the UK public sector (NHS trusts, hospitals, and clinics) with anticipation of the first deployments to take place in 2025. We estimate the market potential for the tender, only in the public sector in the UK (excluding private hospitals and clinics), is estimated at over $50 million annually. Seegnal's parent company signed a definitive agreement with REEM Capital Corp. TSXV:REEM to list on the Toronto Stock Exchange Congratualtions Eyal Schneid and the Seegnal dedicated team for an excellent job !!! Shiri Guy Alfandary, PharmD. Timi Gilat, Adv. Jack Steckel Jonathan Held, CPA, CA Michael Saliken Jonathan Holmes Gadi Levin Yossi Boker

#nowlive #happeningnow We are thrilled to be live at the 8th Annual Medical Device Regulatory and Quality Summit 2024 in New Delhi! Currently, we are deep into an insightful and dynamic Guru Regulatory Panel Discussion on the "Overview of Current Regulations Governing Medical Devices in India, Including Recent Updates and Upcoming Changes." The distinguished panelists are providing diverse perspectives, making this a highly valuable session for all attendees. Stay tuned for more updates from this enriching event! Moderator: Sudhakar Mairpady, Director- Regulatory and Government Affairs (South Asia), Becton and Dickinson India Pvt Ltd. Panellists: Shri. Aseem Sahu, Deputy Drugs Controller (India), Central Drugs Standard Control Organisation (HQ), Ministry of Health & Family Welfare, DGHS, Government of India. Dr. Vivekanandan Kalaiselvan, Senior Principal Scientific Officer, Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India Shri. Rajiv Nath, Managing Director, Hindustan Syringes & Medical Devices Ltd. & Forum Coordinator, Association of Indian Medical Device Industry (AiMeD) #MedDeviceSummit2024 #RegulatoryCompliance #QualityAssurance #MedicalDeviceRegulations #DeviceQuality #HealthcareInnovation #CDSCORegulations #MedicalDeviceStandards #RegulatoryAffairs #QualityManagement #MedicalDeviceIndustry #RegulatoryUpdates #MedTech2024 #ComplianceMatters #ClinicalEvalution #MDRcertification #ProductRegulations #MedicalDeviceClassification #PatientSafety #MedicalDeviceWaste #EwasteofMedicaldevices

Opportunity to Experience the MediSupport Program Introduced by Indream Healthcare <Start a New Beginning in Health Management with MediSupport> The health management of our beloved family is one of the most important tasks for all of us. With the advancement of society, the elderly population is rapidly increasing, requiring more careful attention, love, and effort in managing the health of our parents and grandparents. Drug interactions and side effects are always crucial considerations in family health management. Accordingly, Indream Healthcare offers the opportunity to experience its innovative digital healthcare solution, the MediSupport Program. This program aims to enhance patient safety and health promotion by providing real-time information on potential side effects and drug interactions during polypharmacy management. * How to Participate 1. Take a photo of your medication list: Please take a photo of the prescription or the medicine pouch that shows all the medications you are taking at home so that the names are visible. 2. Provide basic information: Please fill in your phone number, age, and gender. 3. Email submission: Send the above information and photos to [cs@indream-healthcare.com] to complete your registration! * Benefits of Participation - Drug Interaction Reporting: Receive a detailed report including information on interactions and side effects based on your medication list through the MediSupport Program. - News on Indream MyChart App: Participants will be the first to receive the latest news about the upcoming patient app 'Indream MyChart'.

Pradhan Mantri Jan Aushadhi Yojna has been a huge success in bringing affordable medicine to Indian public. The scheme started in UPA had initial success and then was stagnating and on brink of failure. Towards the end of NDA 1, the scheme took off and has been one of the most successful government policies for public health. There are exceptions too, where in an open market one can find a handful of the thousand plus medicines at a cheaper rate. There have been occasional issues of under staffing of these centers but on a whole this is unparalleled globally, with prices of the same medicine compared to both Indian market or West (10 to 100 fold) available at the same quality but very low prices. The trick is the right public-private partnership and not a subsidy model. Here is a comprehensive book from scientists at my company, Ioncure Tech Pvt. Ltd., physicians, and pharmacists. https://lnkd.in/gabFECJ6

Real people need consults with real Drs/GPs, not automated algorithms…. Continuity of care - our best, safest model of care. See your GP. #PrimaryCare #GeneralPractice